COYA 302 — Initial data
2H 2026
• 2H 2026: Report additional single-cell proteomics data from the completed ALS and AD investigator-initiated trials.Source filing
COYA biotech catalysts & pipeline
COYA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
COYA 303 — Full data
2H 2026
2H 2026: Publication of in vivo COYA 303 data in inflammatory animal model of peripheral and CNS inflammation.Source filing
ALSTARS — Topline data
Q1 2027
On January 20, 2026, Coya Therapeutics, Inc. (the "Company") issued a letter to its stockholders wherein it announced its cash balance as of December 31, 2025 was $46.8 million (unaudited) with projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2 trial in the first quarter of 2027.Source filing
COYA 302 — Topline data
Q1 2027
Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027.Source filing